Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Fortress Biotech Inc FBIO

Alternate Symbol(s): FBIOP

Healthcare Biotechnology

Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has seven marketed prescription pharmaceutical products and over 25 programs in development at the Company, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions... see more

Add To Watchlist

Recent & Breaking News (NDAQ:FBIO)

Checkpoint Therapeutics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

GlobeNewswire August 30, 2018

National Holdings Corporation Announces Expansion of Capital Markets Team

GlobeNewswire August 20, 2018

Avenue Therapeutics Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights

GlobeNewswire August 14, 2018

Mustang Bio Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights

GlobeNewswire August 13, 2018

Checkpoint Therapeutics Announces Clinical Data on EGFR Inhibitor CK-101 Selected for Late-Breaking Oral Presentation at IASLC 19th World Conference on Lung Cancer

GlobeNewswire August 13, 2018

Mustang Bio and St. Jude Children’s Research Hospital Enter into Exclusive Worldwide License Agreement for a Ground-Breaking, Clinical-Stage Lentiviral Gene Therapy with Curative Potential for X-linked Severe Combined Immunodeficiency

GlobeNewswire August 13, 2018

Fortress Biotech Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights

GlobeNewswire August 9, 2018

Mustang Bio to Present at 10th Annual Bioprocessing Summit

GlobeNewswire August 9, 2018

Checkpoint Therapeutics Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights

GlobeNewswire August 7, 2018

Fortress Biotech Announces Aevitas Therapeutics Enters Sponsored Research Agreement with the University of Pennsylvania to Advance AAV Gene Therapy Technology

GlobeNewswire August 6, 2018

National Holdings Appoints Henry E. Kaplan as President and Chief Operating Officer of National Asset Management

GlobeNewswire July 23, 2018

National Holdings Corporation Announces Round of Executive Promotions

GlobeNewswire July 20, 2018

Mustang Bio Completes Pre-IND Meeting with FDA for MB-102 (CD123 CAR T)

GlobeNewswire July 19, 2018

Fortress Biotech Announces Cyprium Therapeutics’ CUTX-101 (Copper Histidinate) Granted FDA Fast Track Designation for Treatment of Classic Menkes Disease

GlobeNewswire July 2, 2018

Caelum Biosciences Announces Complete Cardiac Data Analysis from Phase 1b Trial of CAEL-101 in AL Amyloidosis

GlobeNewswire June 25, 2018

Mustang Bio Added to Russell 2000®, 3000® and Microcap® Indexes

GlobeNewswire June 25, 2018

Mustang Bio Announces Opening of CAR T Cell Therapy Manufacturing Facility in Worcester, Mass.

GlobeNewswire June 22, 2018

Avenue Therapeutics to Participate in JMP Securities Life Sciences Conference

GlobeNewswire June 19, 2018

Fortress Biotech Announces Publication of Phase 1 Data on CNDO-109-Activated Allogeneic Natural Killer Cells in Acute Myeloid Leukemia in Biology of Blood and Marrow Transplantation

GlobeNewswire June 19, 2018

Caelum Biosciences Announces Presentation of Complete Cardiac Data Analysis from Phase 1b Trial of CAEL-101 in AL Amyloidosis at American Society of Echocardiography 29th Annual Scientific Sessions

GlobeNewswire June 18, 2018